Akeso Secures FDA Approval for Cadonilimab Trial
In a significant milestone for the biopharmaceutical landscape, Akeso, Inc. (9926.HK) has received FDA approval to launch its global multicenter Phase III trial known as COMPASSION-37. This study will focus on cadonilimab, an innovative PD-1/CTLA-4 bispecific antibody, specifically designed to combat gastric cancer. The trial will evaluate cadonilimab in conjunction with chemotherapy, in comparison to traditional chemotherapy regimens that may or may not include nivolumab, for treating unresectable or metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma.
Advancing Global Strategies in Oncology
This upcoming trial marks the second international registrational study for cadonilimab, following its ongoing examination in the treatment of immunotherapy-resistant hepatocellular carcinoma. The COMPASSION-37 trial signifies a pivotal step in both cadonilimab's development and Akeso's broader mission within the global immuno-oncology sphere. The company intends to leverage its strategic collaborations and proprietary research to expedite the availability of cadonilimab for patients worldwide.
The Challenge of Treatment Variability
The current standards for advanced gastric cancer generally involve chemotherapy with PD-1 inhibitors, such as nivolumab. However, distinct patient populations exhibit vastly varying responses due to the heterogeneous nature of the disease. Although PD-1 therapies combined with chemotherapy have shown promise for patients with high PD-L1 expression levels, the same cannot be said for those with low or absent PD-L1 expression. This challenge is particularly concerning since patients with these lower levels represent a significant majority of the gastric cancer population.
Changing Landscape of Gastric Cancer Treatment
Recent regulatory updates have highlighted particular limitations for PD-1 inhibitors, restricting their application in advanced gastric cancer initially to only PD-L1-positive patients. Prestigious guidelines such as those from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) chiefly advocate for the use of nivolumab in patients demonstrating PD-L1 CPS ?5. This reality underscores the urgent need for effective treatments tailored for patients with low or negative PD-L1 expression.
Proven Efficacy of Cadonilimab
In light of these challenges, the results from the COMPASSION-15 study have been promising. In recent findings, cadonilimab, in combination with chemotherapy, was approved in China as the first-line treatment for gastric cancer, showing benefits for both PD-L1 positive and negative patients. The COMPASSION-15 trial remains a standout due to its comprehensive representation of underrepresented patient groups, proving cadonilimab's potential efficacy in patients traditionally classified as difficult to treat.
Long-term Analysis and Promising Outcomes
Long-term data from the COMPASSION-15 study revealed that cadonilimab combined with chemotherapy reduced the risk of mortality by 39% across the overall study population compared to traditional control measures. Notably, in patients exhibiting PD-L1 CPS ?5, this reduction soared to 51%. Even among patients with low PD-L1 expression (CPS <5), a significant decline in mortality by 24% was observed, suggesting that cadonilimab offers broader therapeutic potential across various expressions of PD-L1.
About Akeso
Founded in 2012, Akeso (HKEX: 9926.HK) dedicates itself to the innovation and development of cutting-edge biopharmaceuticals, striving to deliver the next generation of biological therapies. By cultivating a unique R&D ecosystem with the esteemed ACE Platform and Tetrabody technology, alongside a robust pipeline of over 50 innovative candidates targeting various diseases, Akeso is at the forefront of biopharmaceutical advancements. The company remains devoted to providing innovative and affordable treatments globally and creating significant social value within the healthcare sector.
Frequently Asked Questions
What is cadonilimab?
Cadonilimab is a first-in-class bispecific antibody that targets PD-1 and CTLA-4, developed by Akeso for the treatment of various cancers.
What does the COMPASSION-37 trial involve?
The COMPASSION-37 trial is a global Phase III study that evaluates cadonilimab in combination with chemotherapy against traditional chemotherapy regimens for gastric cancer patients.
Why is the FDA approval significant?
This FDA approval is crucial as it enables the advancement of cadonilimab in treating a challenging and diverse patient population with gastric cancer globally.
How does cadonilimab compare to other treatments?
Cadonilimab shows broad efficacy even in patients with low or negative PD-L1 expression, setting it apart from many existing PD-1 inhibitors that are limited to high PD-L1 levels.
What is Akeso's mission?
Akeso aims to develop innovative biopharmaceuticals and enhance cancer treatment options globally through research, development, and commercialization of their groundbreaking therapies.
